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Aim
The purpose of this exhibit is to describe and compare the
high-resolution MRI features of rectal carcinoma after
chemoradiation treatment (CRT) and to correlate with the
histologic findings after total mesorectal excision (TME).
Method
High resolution T2-W MR imaging (HRMRI) was per-
formed in a 1.5 T unit between January 2013 and February
2014 before and immediately after CRT in the care of
25 patients with locally advanced adenocarcinoma of
the rectum. After total mesorectal excision (TME) the
piece was cut by the pathologist under the supervision of
the radiologist, who indicated areas of residual tumour
after neoadjuvant therapy or changes such as fibrosis,
oedema, cellular and acellular mucin, desmoplastic reac-
tion and pseudotumour appearance. Thus, initially we did
a correlation between the macroscopic and MR imaging.
Subsequently, we performed the same correlation but
in this case between microscopy and MR imaging.
Changes in morphologic and signal intensity features were
evaluated with respect to primary tumour and nodal
downstaging.
Summary
Emerging evidence has shown the prognostic importance
of reassessing rectal cancer using HRMRI after completion
of CRT. A systematic cooperation between radiologist and
pathologist is essential for optimal treatment planning and
patient care.
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